Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections

Ophthalmic Surgery Lasers and Imaging

Volumn 40, Issue 3, 2009, Pages 293-295

  Kahook, Malik Y ^a   Kimura, Alan E ^b   Wong, Lisa J ^a   Ammar, David A ^a   Maycotte, Marco A ^a   Mandava, Naresh ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Ophthalmic Technician   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRIMONIDINE; BRINZOLAMIDE; LATANOPROST; MITOMYCIN C; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; EYE EXAMINATION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MALE; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIHYPERTENSIVE AGENTS; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; MIDDLE AGED; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 67149143227     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20090430-12     Document Type: Article

References (8)

1. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511. (Pubitemid 44620390)
2. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349. (Pubitemid 44702055)
3. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81-87. (Pubitemid 350167096)
4. Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye. 2007;21:1541.
5. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146:930-934.
6. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512.
7. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335-345. (Pubitemid 40767935)
8. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536-544. (Pubitemid 29446822)